Novavax, Inc. (LON:0A3S)
London flag London · Delayed Price · Currency is GBP · Price in USD
6.42
-0.06 (-0.93%)
At close: Jun 27, 2025

Novavax Company Description

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.

The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
Country United States
Founded 1987
Industry Biological Products, Except Diagnostic Substances
Employees 952
CEO John Jacobs

Contact Details

Address:
700 Quince Orchard Road
Gaithersburg, Delaware 20878
United States
Phone 240 268 2000
Website novavax.com

Stock Details

Ticker Symbol 0A3S
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
John Charles Jacobs M.B.A. President, Chief Executive Officer and Director
James Patrick Kelly C.F.A. Executive Vice President, Chief Financial Officer and Treasurer
Mark J. Casey Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Elaine O'Hara Executive Vice President and Chief Strategy Officer
Richard P. Crowley Executive Vice President and Chief Operating Officer
Troy Morgan Esq., J.D. Senior Vice President, Deputy General Counsel and Chief Compliance Officer
Erika S. Trahan Associate Director of Investor and Public Relations
Ian J. Watkins Executive Vice President and Chief Human Resources Officer
Silvia Taylor M.B.A. Executive Vice President and Chief Corporate Affairs and Advocacy Officer
Dr. Henrietta Ukwu FACP FRAPS, M.D. Executive Vice President and Chief Regulatory Officer